Fontana Fabrizio, Anselmi Martina, Limonta Patrizia
Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Department of Pharmacological and Biomolecular Sciences, University of Milan, Milan, Italy.
Cancer Lett. 2022 May 28;534:215619. doi: 10.1016/j.canlet.2022.215619. Epub 2022 Mar 8.
Prostate cancer remains one of the most lethal malignancies among men worldwide. Although the primary tumor can be successfully managed by surgery and radiotherapy, advanced metastatic carcinoma requires better therapeutic approaches. In this context, a deeper understanding of the molecular mechanisms that underlie the initiation and progression of this disease is urgently needed, leading to the identification of new diagnostic/prognostic markers and the development of more effective treatments. Herein, the current state of knowledge of prostate cancer genetic alterations is discussed, with a focus on their potential in tumor detection and staging as well as in the screening of novel therapeutics.
前列腺癌仍然是全球男性中最致命的恶性肿瘤之一。尽管原发性肿瘤可以通过手术和放疗成功治疗，但晚期转移性癌需要更好的治疗方法。在这种背景下，迫切需要更深入地了解该疾病发生和发展的分子机制，从而识别新的诊断/预后标志物并开发更有效的治疗方法。本文讨论了前列腺癌基因改变的当前知识状态，重点关注它们在肿瘤检测、分期以及新型治疗药物筛选方面的潜力。
